By combining your genetic predisposition data with baseline biomarkers (insulin, glucose, inflammatory markers, lipids) and clinical history, you and your provider can make a more informed decision about whether maintenance GLP-1 therapy, alternative compounds, or intensive behavioral interventions are most likely to support sustainable weight maintenance for your specific situation
California residents have additional consumer protection rights under California law and additional disclosure rights as noted in Sunlight's Telehealth Consent Form
Multiple clinical trial findings have illuminated the favorable clinical activity of CB-839 alongside minimal adverse reactions [212,213,214,215,216]
Ongoing visits help the physician review: Whether the patient is making meaningful progress Whether the dose should change Whether side effects are developing Whether another treatment would be safer or more effective Whether nutrition or activity changes are needed Patients should choose a physician-supervised injection program with regular evaluation and follow-up
Over 1,400 actions were pending in the MDL as of October 2024